CEPI awards US$ 34M contract to CureVac to advance The RNA Printer™—a disruptive, transportable mRNA vaccine manufacturing platform that can rapidly combat multiple diseases
The Coalition for Epidemic Preparedness Innovations (CEPI) and CureVac AG, a biopharmaceutical company pioneering the field of mRNA-based vaccines, have announced a partnership agreement worth up to US$ 34 million for the ongoing development of The RNA Printer™ prototype—a transportable, down-scaled, automated messenger RNA (mRNA) printing facility. This innovative platform will provide a rapid supply of lipid-nanoparticle (LNP)-formulated mRNA vaccine candidates that can target known pathogens (including Lassa Fever, Yellow Fever, and Rabies) and prepare for rapid response to new and previously unknown pathogens (referred to by WHO as “Disease X”).